Introduction: Hepatitis B (HBV) and Hepatitis C (HCV) are serious global health problems affecting millions of people around the globe. About 1.5 million people die every year from HBV and HCV related chronic liver diseases such as end stage cirrhosis and Hepatocellular carcinoma (HCC) worldwide[2]. Material and Methods: Present Hospital based prospective study was conducted in the Department of microbiology K. D. Medical College Hospital and Research Centre. Duration of the present study was 6 months (September 2017 to March 2018). 100 serum samples for HBsAg and 100 serum sample for Anti HCV were included in this study. Results: for HBV, specificity was 96.7% and the Positive Predictive value (PPV) was 70%. However, the sensitivity was 77.8% and the Negative Predictive value (NPV) was 97.7% and for HCV, specificity was 93.1% and the Positive Predictive value(PPV) was 57.1%. However, the sensitivity was 61.6% and the Negative Predictive value (NPV) was 94.2%. Conclusion: In our study we concluded that Immuno Chromatographic Assay is less efficient than ELISA. No specific treatment and long term serious complications of HBV and HCV are highly dangerous for community; missing a positive case leave a threat of silent transmission and spreading of diseases among people and also create an urge for more sensitive assays like ELISA. Use of Immuno Chromatographic Assay should be recommended only in poor settings, remote areas and peripheral health facilities.
